The success of a recent drug trial for omega 3 could open doors for further research in the effects of these ingredients, particularly at high doses, says a prominent expert from the field.
William Harris, a PhD from the South Dakota University has invested many years of his career on researching these ingredients’ effects. According to Harris, the recent successful results of Amarin’s Reduce-It trail conducted on the company’s Vascepa medication could help to reinvigorate research on high dose omega 3 trials.
The Amarin’s trial involved over 8000 patients and was conducted for a span of 8 years. The results of the trial, which appears in the England Journal of Medicine, revealed a 25 percent reduction in severe cardiovascular disease risk.
Omega 3 Index shows the levels of omega 3 in terms of percentage, with 4 percent being the average noticed among North American residents and 8 percent or more being the level where these ingredients begin having more of cardio-protective effects.
The present dietary habits call for consuming fish a few times in a week for high doses of omega 3; however that would not go far enough. So, if it gets proven that high doses of omega 3 could help attain huge health benefits, Harris said that it would therefore make a powerful case for omega 3 supplementation.